 |
AIDSinfo E-News: Offering HIV/AIDS Research, Clinical Trials, Prevention, and Treatment Information. |
|
AIDSinfo At-a-Glance Issue No. 32September 23, 2005 AIDSinfo.nih.gov is pleased to provide you with a weekly update of highlights about what has happened in the world of HIV/AIDS treatment, prevention, and research. We hope you find this encapsulated view of HIV/AIDS news useful. Recommendations for Non-HIV-Specialized Providers
Caring for Displaced HIV-Infected Residents from the Hurricane
Disasters—
Essential
Information for Managing HIV-Infected Patients Receiving Antiretroviral
Therapy Some
HIV-infected patients may have interrupted their antiretroviral therapy
and other medications due to the recent hurricane disasters. The following information provides
some guidance to the general practitioners attending to the medical needs
of displaced HIV-infected adult or pediatric patients who have not yet
secured HIV care in the local area.
Management
of antiretroviral therapy is complex and should best be done with the
assistance of specialized clinicians. Medical consultation may also be
available at specific local or regional HIV clinics or via the 24-hour NIH Medical Consultation
Services at 1-866-887-2842 or the National HIV Telephone Consultation
Service: at 1-800-933-3413. For a more
in-depth look at these recommendations
HIV Drug Trial Halted Due to Liver
Toxicity
AIDSinfo
staff attended the Treatment and
Management of HIV Conference in Atlanta, Georgia, last week,
where there was a lot of discussion about CCR5 inhibitors. During that
same week, GlaxoSmithKline
PLC announced that it had halted safety and efficacy trials of the CCR5
inhibitor aplaviroc,
after 2 of the 250 treatment-naïve trial participants developed severe
liver toxicity. However, studies of aplaviroc are continuing among 40
treatment-experienced participants whose virus is resistant to currently
approved treatments. Other
investigational CCR5 inhibitors include maraviroc
and vicriviroc. PubMed
provides access to a comprehensive
review of entry inhibitors, including CCR5 inhibitors.
ClinicalTrials.gov InfoFor information about CCR5 inhibitor clinical trials go to:
ClinicalTrials.gov.
New HIV/AIDS trials have been
added to ClinicalTrials.gov in the last 7 days. Please send comments or
suggestions to ContactUs@aidsinfo.nih.gov
|
|
|
|
You are currently subscribed to %%list.name%% as:
%%emailaddr%% Subscribe to AIDSinfo list serv here. |
|
Contact AIDSinfo Click on the Live Help button on the AIDSinfo home page and communicate with the staff in “real time.” |